Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics: Mark Pollack

Myriad Genetics has named Mark Pollack as chief medical officer of Myriad Neuroscience. Pollack will start in this new role on Jan. 15, 2020, and will report to Mark Verratti, president of the neuroscience division. In this position, Pollack will be in charge of efforts to integrate the GeneSight pharmacogenetic test into clinical practice. Pollack is a psychiatrist with three decades of experience in clinical psychiatry and neuroscience. He served as professor and chair of the psychiatry department at Rush University Medical Center in Chicaco, and before that he was a psychiatry professor at Harvard Medical School and directed the Center of Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.